专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006089658A3 NK1 ANTAGONISTS 审中-公开
标题翻译： NK1拮抗剂
公开(公告)号：WO2006089658A3
公开(公告)日：2006-12-21
申请号：PCT/EP2006001310
申请日：2006-02-14
申请人： HOFFMANN LA ROCHE , HOFFMANN TORSTEN , SCHNIDER PATRICK
发明人： HOFFMANN TORSTEN , SCHNIDER PATRICK
IPC分类号： C07D213/75 , A61K31/44 , A61P25/18 , C07D213/82
CPC分类号： C07D213/75 , C07D213/82
摘要： The present invention relates to compounds of the formula (I), wherein R 1 /R 1' are hydrogen or methyl; X is -C(O)N(CH 3 )- or -N(CH 3 )C(O)-; and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic or psychosomatic disorders.
摘要翻译：本发明涉及式（I）的化合物，其中R 1，R 1，R 1'是氢或甲基; X是-C（O）N（CH 3） - 或-N（CH 3）C（O） - ; 及其药学上可接受的酸加成盐用于治疗许多炎性疾病，偏头痛，类风湿性关节炎，哮喘，炎性肠病，催吐反射介导，帕金森病，焦虑症，抑郁症，精神病，晕动病，诱发的呕吐，疼痛，头痛，偏头痛，阿尔茨海默病，多发性硬化症，吗啡戒断减弱，心血管改变，水肿如热损伤引起的水肿，慢性炎性疾病如类风湿性关节炎，哮喘/支气管高反应性和其他呼吸系统疾病，包括过敏性鼻炎，炎性疾病包括溃疡性结肠炎和克罗恩病，眼部损伤和眼部炎性疾病，创伤性脑损伤，晕动病，呕吐和精神免疫或心身疾病。

2. 发明申请

WO03011860A3 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1lambd6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE 审中-公开
标题翻译： 2-（3,5-双 - 三氟甲基 - 苯基）-N- [6-（1,1-二氧代-1-氨基-6-吗啉-4-基）-4-（2-甲基或4-氟-2-甲基取代的）苯基 - 吡啶-3-基] -N-甲基 - 异丁酰胺
公开(公告)号：WO03011860A3
公开(公告)日：2003-09-04
申请号：PCT/EP0208311
申请日：2002-07-26
申请人： HOFFMANN LA ROCHE
发明人： BALLARD THERESA MARIA , HOFFMANN TORSTEN , POLI SONIA MARIA , SCHNIDER PATRICK , SLEIGHT ANDREW
IPC分类号： A61K31/541 , A61P1/00 , A61P1/08 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/02 , A61P13/08 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D213/75
CPC分类号： C07D213/75
摘要： The invention relates to the compounds 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambd6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambd6 -thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, which may be used for the treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease or for the treatment of disorders including Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis,oedema, allergic rhinitis, Crohn's disease, ocular injury, ocular inflammatory diseases, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunologic or psychosomatic disorders, cancer, withdrawel symptoms of addictive drugs from opiates or nicotine, traumatic brain injury or benign prostatic hyperplasia.
摘要翻译：本发明涉及化合物2-（3,5-双 - 三氟甲基 - 苯基）-N- [6-（1,1-二氧代-1,11-硫代吗啉-4-基）-4-邻甲苯基 - 吡啶-3-基 - 基] -N-甲基 - 异丁酰胺和2-（3,5-双 - 三氟甲基 - 苯基）-N- [6-（1,1-二氧代-1-氨基-6-硫代吗啉-4-基）-4-（4- 氟-2-甲基 - 苯基） - 吡啶-3-基] -N-甲基 - 异丁酰胺，其可用于治疗偏头痛，类风湿性关节炎，哮喘，支气管高反应性，炎性肠病或用于治疗疾病，包括帕金森病，焦虑症，抑郁症，疼痛，头痛，阿尔茨海默氏病，多发性硬化症，水肿，过敏性鼻炎，克罗恩病，眼部损伤，眼部炎症性疾病，精神病，运动病，诱发性呕吐，呕吐，尿失禁，心理免疫或心身疾病，癌症，从阿片剂或尼古丁，外伤性脑损伤或良性前列腺增生症中消除上瘾药物的症状。

3. 发明申请

WO03006016A3 USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY 审中-公开
标题翻译： NK-1受体拮抗剂与吡啶结构的用途，用于治疗脑，脊髓或神经损伤
公开(公告)号：WO03006016A3
公开(公告)日：2003-07-31
申请号：PCT/EP0207323
申请日：2002-07-03
申请人： HOFFMANN LA ROCHE
发明人： HOFFMANN TORSTEN , NIMMO ALAN JOHN , SLEIGHT ANDREW , VANKAN PIERRE , VINK ROBERT
IPC分类号： C07D213/74 , A61K31/435 , A61K31/4418 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61K31/541 , A61K39/395 , A61P1/04 , A61P1/08 , A61P11/06 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/75 , C07D213/82 , C07D401/04 , C07D401/12 , C07D409/04 , C07D413/04 , C07D413/12
CPC分类号： A61K31/435
摘要： The invention relates to the use of an NK-1 receptor antagonist, optionally in combination with a magnesium salt, for the treatment and/or prevention of brain, spinal or nerve injury, wherein said NK-l receptor antagonist is a compound of the general formula (I) wherein the meanings of R, R , R , R , R , R are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-( 4-methyl-piperazin-l-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising one or more such NK-l receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.
摘要翻译：本发明涉及NK-1受体拮抗剂（任选与镁盐组合）用于治疗和/或预防脑，脊髓或神经损伤的用途，其中所述NK-1受体拮抗剂是一般化合物 R 1，R 2，R 2，R 2'，R 3，R 4的含义在说明书和药学上可接受的酸加成盐和前体药物中解释的式（I）单独或与镁盐组合。举例说明了使用N-（3,5-双 - 三氟甲基 - 苄基）-N-甲基-6-（4-甲基 - 哌嗪-1-基）-4-邻甲苯基 - 烟酰胺。本发明还涉及包含一种或多种这样的NK-1受体拮抗剂，任选与镁盐组合的药物组合物和用于治疗和/或预防脑，脊髓或神经损伤的药学上可接受的赋形剂。

4. 发明申请

WO0050398A3 PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS 审中-公开
标题翻译：苯并吡啶衍生物作为神经营养因子1拮抗剂
公开(公告)号：WO0050398A3
公开(公告)日：2001-04-05
申请号：PCT/EP0001224
申请日：2000-02-15
申请人： HOFFMANN LA ROCHE
发明人： BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC分类号： C07C211/44 , A61K31/167 , A61K31/44 , A61P25/00 , A61P29/00 , C07C211/54 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/14 , C07C317/40 , C07C323/41 , C07D213/75 , C07D213/79 , C07D213/81 , C07D295/12 , C07D295/135 , C07D401/04
CPC分类号： C07D213/75 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/40 , C07C323/41 , C07D295/135
摘要： The invention relates to compounds of general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R is independently from each other hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, halogen, lower alkyl, lower alkoxy, -N(R )2, -N(R )S(O)2-lower alkyl, -N(R )C(O)R or a cyclic tertiary amine of the group (a); R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R ) C(O)-, C(O)O- or -N(R )(CH2)m-; Y is -(CH2)n-, -O-, -S-, SO2-, -C(O)- or -N(R )-; Z is =N-, -CH= or -C(C1)=; n is 0 - 4; and, is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds of formula (I) have a high affinity to the NK-1 receptor.
摘要翻译：本发明涉及通式（I）的化合物，其中R是氢，低级烷基，低级烷氧基，卤素或三氟甲基; R 1是氢或卤素; 或R和R 1可以一起是-CH = CH-CH = CH-; R 2是氢，卤素，三氟甲基，低级烷氧基或氰基; R 3彼此独立地为氢，低级烷基或形成环烷基; R 4是氢，卤素，低级烷基，低级烷氧基，-N（R 5）2，-N（R 5）S（O）2-低级烷基，-N（R 5） C（O）R 5或（a）组的环状叔胺; R 5彼此独立地为氢，C 3-6 - 环烷基，苄基或低级烷基; R 6是氢，羟基，低级烷基，-N（R 5）CO-低级烷基，羟基 - 低级烷基，氰基，-CHO或5-或6-元杂环基，任选经由亚烷基键合，X是-C（O）N（R 5） - ， - （CH 2）m O - ， - （CH 2）m N（R 5） - ， - N（R 5）C（O），C（O）O-或-N（R 5）（CH 2）m - ; Y是 - （CH 2）n - ， - O - ， - S - ，SO 2 - ， - C（O） - 或-N（R 5） Z是= N-，-CH =或-C（C1）=; n为0-4; 是1或2; 及其药学上可接受的酸加成盐。已经表明式（I）化合物对NK-1受体具有高亲和力。

5. 发明申请

WO0073278A2 5-PHENYL-PYRIMIDINE DERIVATIVES 审中-公开
标题翻译： 5-苯基 - 吡啶衍生物
公开(公告)号：WO0073278A2
公开(公告)日：2000-12-07
申请号：PCT/EP0004702
申请日：2000-05-24
申请人： HOFFMANN LA ROCHE
发明人： BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC分类号： A61K31/505 , A61K31/506 , A61K31/513 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/02 , A61P11/06 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/00 , C07D239/00 , C07D239/28 , C07D239/34 , C07D239/38 , C07D239/42 , C07D239/46 , C07D239/48 , C07D295/00 , C07D401/04
CPC分类号： C07D239/28 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/48
摘要： The invention relates to compounds of general formula (I) wherein R is hydrogen or halogen; R is hydrogen, halogen, lower alkyl or lower alkoxy; R is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R /R are independently from each other hydrogen or lower alkyl; R is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, -(CH2)n-piperazinyl, optionally substituted by lower alkyl, -(CH2)n-morpholinyl, -(CH2)n+1-imidazolyl, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R )2, -(CH2)n-NH-(CH2)n+1N(R )2, -(CH2)n+1N(R )2, or -O-(CH2)n+1N(R )2, wherein R is hydrogen or lower alkyl; R is hydrogen; R and R or R and R may be together with the two carbon ring atoms -CH=CH-CH=CH-, with the proviso that n for R is 1; n is independently 0 - 2; and X is -C(O)N(R )- or -N(R )C(O)-; and pharmaceutically acceptable acid addition salts thereof. Compounds of formula (I) have a high affinity to the NK-1 receptor. They are therefore useful for the treatment or diseases which relate to this receptor.
摘要翻译：本发明涉及通式（I）的化合物，其中R 1是氢或卤素; R 2是氢，卤素，低级烷基或低级烷氧基; R 3是卤素，三氟甲基，低级烷氧基或低级烷基; R 4 / R 4彼此独立地为氢或低级烷基; - （CH 2）n - 吗啉基， - （CH 2）n + 1-烷基， - （CH 2）n - 咪唑基，-O-（CH 2）n + 1-吗啉基，-O-（CH 2）n + 1-哌啶基，低级烷基 - 硫烷基，低级烷基 - 磺酰基，苄基氨基，-NH-（CH 2）n + 4“>）2， - （CH 2）n -NH-（CH 2）n + 1N（R 4”）2， - （CH 2）n + 1N（R 4“）2或-O- CH 2）n + 1N（R 4“）2，其中R 4是氢或低级烷基; R 6是氢; R 2和R 6或R 1和R” 6>可以与两个碳环原子-CH = CH-CH = CH-一起，条件是R 1的n为1; n独立地为0-2;且X为-C（O）N （R 4） - 或-N（R 4）C（O） - 及其药学上可接受的酸加成盐。式（I）化合物对NK-1受体具有高亲和力因此可用于与该受体相关的治疗或疾病。

6. 发明申请

WO2011131748A3 BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE 审中-公开
标题翻译：作为谷氨酰胺环化酶抑制剂的苯唑咪唑衍生物
公开(公告)号：WO2011131748A3
公开(公告)日：2012-03-15
申请号：PCT/EP2011056396
申请日：2011-04-21
申请人： PROBIODRUG AG , HEISER ULRICH , RAMSBECK DANIEL , HOFFMANN TORSTEN , BOEHME LIVIA
发明人： HEISER ULRICH , RAMSBECK DANIEL , HOFFMANN TORSTEN , BOEHME LIVIA
IPC分类号： C07D209/08 , A61K31/4184 , A61P25/00 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/12 , C07D417/14
CPC分类号： C07D209/08 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/12 , C07D417/14
摘要： The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
摘要翻译：本发明涉及作为谷氨酰胺酰环化酶抑制剂的新型杂环衍生物（QC，EC 2.3.2.5）。 QC在氨释放下催化N-末端谷氨酰胺残基在焦谷氨酸（5-氧代 - 脯氨酰基，pGlu *）中的分子内环化，并且在释放水下将N-末端谷氨酸残基分子内环化成焦谷氨酸。

7. 发明申请

WO2009090190A1 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE 审中-公开
标题翻译：携带GLUTAMINYL CYCLASE基因的锁定突变的小鼠模型
公开(公告)号：WO2009090190A1
公开(公告)日：2009-07-23
申请号：PCT/EP2009050387
申请日：2009-01-14
申请人： PROBIODRUG AG , DEMUTH HANS-ULRICH , HOFFMANN TORSTEN , SCHILLING STEPHAN
发明人： DEMUTH HANS-ULRICH , HOFFMANN TORSTEN , SCHILLING STEPHAN
IPC分类号： C12N15/54 , A01K67/027 , A61K35/00 , C12N5/10 , C12N9/10 , G01N33/50
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N9/104 , C12N15/8509 , C12N2800/30 , G01N2500/00 , G01N2800/2814
摘要： The present invention provides a knock-out non-human animal, in particular a mouse carrying a glutaminyl cyclase (EC 2.3.2.5) knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
摘要翻译：本发明提供了敲除非人动物，特别是携带谷氨酰胺环化酶（EC 2.3.2.5）敲除突变的小鼠。本发明另外提供了用于评价影响Qpct的药剂的各种细胞和细胞系以及用于评估用于治疗Qpct相关疾病的组合物的方法和组合物。

8. 发明申请

WO2005074983A3 TREATMENT OF RHINITIS WITH ANTICHOLINERGICS ALONE IN COMBINATION WITH ANTIHISTAMINES PHOSPHODIESTERASE 4 INHIBITORS, OR CORTICOSTEROIDS 审中-公开
标题翻译：与抗生素相关的抗病毒药物与抗生素抑制剂4抑制剂或角质素化合物的治疗
公开(公告)号：WO2005074983A3
公开(公告)日：2006-04-13
申请号：PCT/EP2005000653
申请日：2005-01-24
申请人： SOFOTEC GMBH & CO KG , MAUS JOACHIM , PETZOLD URSULA , SZELENYI ISTVAN , HOFFMANN TORSTEN , WEINGART MARIO
发明人： MAUS JOACHIM , PETZOLD URSULA , SZELENYI ISTVAN , HOFFMANN TORSTEN , WEINGART MARIO
IPC分类号： A61K31/401 , A61K31/519 , A61K31/55 , A61K31/573 , A61K39/00 , A61K45/06 , A61P11/00
CPC分类号： A61K45/06 , A61K31/401 , A61K31/519 , A61K31/55 , A61K31/573 , A61K2300/00
摘要： The present invention provides novel combinations comprising a topical anticholinergic drug alone or in combination with topically administered antihistamines, topically or orally administered phosphodiesterase 4 inhibitors or topical corticosteroids for the treatment of rhinitis of various origins. It further comprises presentation of these combinations in locally applied formulations and includes various pharmaceutical formulations suitable for topical application, e.g. nasal sprays, nasal drops, emulsions, pastes, creams and gels.
摘要翻译：本发明提供新颖的组合，其包括单独的局部抗胆碱能药物或局部施用的抗组胺剂，局部或口服给予的磷酸二酯酶4抑制剂或局部皮质类固醇用于治疗各种原因的鼻炎。其还包括在局部施用的制剂中呈现这些组合，并且包括适用于局部应用的各种药物制剂，例如。鼻喷雾剂，滴鼻剂，乳剂，糊剂，霜剂和凝胶剂。

9. 发明申请

WO03002593A3 PEPTIDE STRUCTURES USEFUL FOR COMPETITIVE MODULATION OF DIPEPTIDYL PEPTIDASE IV CATALYSIS 审中-公开
标题翻译：磷酸二酯酶IV竞争性调节有用的肽结构
公开(公告)号：WO03002593A3
公开(公告)日：2003-09-04
申请号：PCT/EP0207128
申请日：2002-06-27
申请人： PROBIODRUG AG , DEMUTH HANS ULRICH , HOFFMANN TORSTEN , MANHART SUSANNE , HOFFMANN MATTHIAS , HEINS JOCHEN
发明人： DEMUTH HANS ULRICH , HOFFMANN TORSTEN , MANHART SUSANNE , HOFFMANN MATTHIAS , HEINS JOCHEN
IPC分类号： A61K38/00 , A61K38/04 , A61K38/06 , A61K38/07 , A61K38/08 , A61P3/00 , A61P3/10 , A61P43/00 , C07K5/00 , C07K5/08 , C07K5/083 , C07K5/087 , C07K5/10 , C07K7/06
CPC分类号： C07K7/06 , A61K38/04 , A61K38/06 , A61K38/07 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812
摘要： The present invention refers to a compound represented by the general formula (I): and pharmaceutically acceptable salts thereof. The compounds can be used for the preparation of a medicament for the prophylaxis or treatment of a condition mediated by modulation of the dipeptidyl peptidase IV activity, wherein the condition preferably is selected from impaired glucose tolerance, diabetes mellitus, glucosuria and metabolic acidosis.
摘要翻译：本发明涉及由通式（I）表示的化合物及其药学上可接受的盐。所述化合物可用于制备用于预防或治疗通过调节二肽基肽酶IV活性介导的病症的药物，其中所述病症优选选自葡萄糖耐量异常，糖尿病，糖尿病和代谢性酸中毒。

10. 发明申请

WO2013127539A3 PHARMACEUTICAL FORMULATION CONTAINING FLUPIRTIN 审中-公开
标题翻译：药物制剂含氟吡汀
公开(公告)号：WO2013127539A3
公开(公告)日：2013-12-19
申请号：PCT/EP2013000615
申请日：2013-03-01
申请人： MEDA PHARMA GMBH & CO KG , MOSCHNER KATRIN , HOFFMANN TORSTEN , WEINGART MARIO , HILDEBRAND-CYRENER ANNEGRET
发明人： MOSCHNER KATRIN , HOFFMANN TORSTEN , WEINGART MARIO , HILDEBRAND-CYRENER ANNEGRET
IPC分类号： A61K9/28 , A61K9/20 , A61K9/50 , A61K31/44
CPC分类号： A61K9/2866 , A61K9/2072 , A61K9/2813 , A61K9/2846 , A61K9/2853 , A61K31/135 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The invention relates to drug preparations with controlled active ingredient released in the form of microtablets which contain, as active ingredient, flupirtin or one of its physiologically compatible salts, and to processes for their production.
摘要翻译：本发明涉及一种具有在包含作为活性成分的氟吡汀或其生理学上可接受的盐和它们的制造过程中的一个微型片剂的形式的活性成分的受控释放的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式